These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32276600)

  • 1. Formononetin inhibits tumor growth by suppression of EGFR-Akt-Mcl-1 axis in non-small cell lung cancer.
    Yu X; Gao F; Li W; Zhou L; Liu W; Li M
    J Exp Clin Cancer Res; 2020 Apr; 39(1):62. PubMed ID: 32276600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deguelin suppresses non-small cell lung cancer by inhibiting EGFR signaling and promoting GSK3β/FBW7-mediated Mcl-1 destabilization.
    Gao F; Yu X; Li M; Zhou L; Liu W; Li W; Liu H
    Cell Death Dis; 2020 Feb; 11(2):143. PubMed ID: 32081857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of EGFR Signaling and Activation of Mitochondrial Apoptosis Contribute to Tanshinone IIA-Mediated Tumor Suppression in Non-Small Cell Lung Cancer Cells.
    Gao F; Li M; Liu W; Li W
    Onco Targets Ther; 2020; 13():2757-2769. PubMed ID: 32308411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non-Small Cell Lung Cancer.
    Ye M; Zhang Y; Zhang X; Zhang J; Jing P; Cao L; Li N; Li X; Yao L; Zhang J; Zhang J
    Cancer Res; 2017 Jul; 77(13):3527-3539. PubMed ID: 28522751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
    Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
    Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and Survivin expression to potentiate ABT-263-induced apoptosis in Non-small Cell Lung Cancer cells harboring EGFR or RAS mutation.
    Yan X; Li P; Zhan Y; Qi M; Liu J; An Z; Yang W; Xiao H; Wu H; Qi Y; Shao H
    Biochem Pharmacol; 2018 Apr; 150():72-85. PubMed ID: 29360439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
    Zhao R; Zhou S; Xia B; Zhang CY; Hai P; Zhe H; Wang YY
    BMC Cancer; 2016 Jul; 16():491. PubMed ID: 27431492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.
    Wu DW; Wu TC; Chen CY; Lee H
    Clin Cancer Res; 2016 Nov; 22(21):5370-5382. PubMed ID: 27178741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
    J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
    Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities.
    Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH
    Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curcumol Exerts Antitumor Effect via Inhibiting EGFR-Akt-Mcl-1 Signaling.
    Li XY; Gao F; Wang XC; Liu LL; Gan Y; Han SZ; Zhou L; Li W; Li M
    Am J Chin Med; 2023; 51(3):741-760. PubMed ID: 36869017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
    Yang Z; Zhang SL; Hu X; Tam KY
    Eur J Pharmacol; 2018 Nov; 838():41-52. PubMed ID: 30213498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycolysis inhibition sensitizes non-small cell lung cancer with T790M mutation to irreversible EGFR inhibitors via translational suppression of Mcl-1 by AMPK activation.
    Kim SM; Yun MR; Hong YK; Solca F; Kim JH; Kim HJ; Cho BC
    Mol Cancer Ther; 2013 Oct; 12(10):2145-56. PubMed ID: 23883584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
    Freeman DJ; Bush T; Ogbagabriel S; Belmontes B; Juan T; Plewa C; Van G; Johnson C; Radinsky R
    Mol Cancer Ther; 2009 Jun; 8(6):1536-46. PubMed ID: 19509246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
    Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling.
    Sun X; Xu Y; Wang Y; Chen Q; Liu L; Bao Y
    Med Sci Monit; 2018 May; 24():3193-3203. PubMed ID: 29763936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model.
    Li H; Wang S; Takayama K; Harada T; Okamoto I; Iwama E; Fujii A; Ota K; Hidaka N; Kawano Y; Nakanishi Y
    Lung Cancer; 2015 Apr; 88(1):1-8. PubMed ID: 25670150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer.
    Zhang Q; Zhang Y; Chen Y; Qian J; Zhang X; Yu K
    Clin Cancer Res; 2019 Jun; 25(12):3630-3642. PubMed ID: 30796032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.